Juan M. Tiraboschi

L'hospitalet De Llobregat, CT 08907, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV.

Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV.

Journal: Microorganisms

Published: March 06, 2026

Knowledge, Attitudes, and Stigma Towards People Living with HIV: An Explanatory Sequential Mixed-Methods Study Among 1013 Healthcare Professionals in Spain.

Knowledge, Attitudes, and Stigma Towards People Living with HIV: An Explanatory Sequential Mixed-Methods Study Among 1013 Healthcare Professionals in Spain.

Journal: Healthcare (Basel, Switzerland)

Published: February 11, 2026

Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.

Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.

Journal: International journal of antimicrobial agents

Published: February 09, 2026

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Journal: Journal of the International AIDS Society

Published: October 11, 2025

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).

Journal: The Journal of antimicrobial chemotherapy

Published: July 17, 2025

Identification of Inflammation Markers as Novel Potential Predictors of the HIV-DNA Reservoir Size.

Identification of Inflammation Markers as Novel Potential Predictors of the HIV-DNA Reservoir Size.

Journal: International journal of molecular sciences

Published: July 15, 2025

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Journal: AIDS (London, England)

Published: July 02, 2025

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Journal: AIDS (London, England)

Published: July 02, 2025

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 24, 2025

Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years.

Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: June 19, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026